TOKYO -- Japanese drugmaker Eisai and U.S. partner Biogen plan to seek regulators' blessing for their new Alzheimer's disease treatment in Japan, Europe and China following Friday's approval in the U.S., the companies said.
Pharmaceuticals
New Alzheimer's drug Leqembi: Eisai, Biogen eye Japan, Europe and China next
FDA-approved treatment will save money spent on nursing care: Eisai CEO
.jpg?width=780&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto)
Eisai and Biogen have won U.S. Food and Drug Administration approval for an Alzheimer's disease treatment for the second time. (Photo by Kosaku Mimura)
Read Next
Latest on Pharmaceuticals
